Navigation Links
Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States
Date:12/2/2008

MALVERN, Pa., Dec. 2 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Ortho-McNeil-Janssen Pharmaceuticals' Levaquin is the preferred quinolone antibiotic among more than half of all general medical-surgical hospitals in the United States. Quinolone antibiotics are used to treat lung, sinus, skin and urinary tract infections caused by numerous bacterial pathogens.

"Based on our October 2008 audit, intravenous Levaquin was stocked in more hospitals than both Bayer's intravenous Cipro and generic intravenous ciprofloxacin combined," stated Matthew W. Mahr, Pharm.D., M.B.A., analyst at AMR.

The newly released edition of the Quinolone Monthly Monitor (U.S.) also finds that over 70 percent of hospitals reported having a closed hospital formulary for antibiotics. Large hospitals were found to be most likely to have a closed formulary for antibiotics. These closed formularies create restrictions on what can be prescribed in the hospital making it more difficult for a prescriber to use that medication.

Why Pharmaceutical Companies Need this Information

The Quinolone Monthly Monitor (U.S.) enables pharmaceutical companies to monitor formulary, stocking and restriction status of selected quinolone antibiotics. This study also gives information about the Pharmacy and Therapeutics Committee's actions for quinolones, which drive formulary and restriction status for these products.

About The Quinolone Monthly Monitor (U.S.)

The Quinolone Monthly Monitor (U.S.) is the industry's most comprehensive market research study of the formulary status of quinolone antibiotics. This study has been conducted monthly since June 1992 by collecting data from 300 pharmacy directors from a group of demographically representative acute care hospitals within the country.

'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. LegalView Reveals Details of the FDA Mandated Black Box Warning For Fluoroquinolone Antibiotics Such as Cipro and Levaquin
2. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
3. Preferred Care Gold Ranked Number One Medicare Advantage Health Plan Nationally In U.S. News & World Report/NCQA Americas Best Health Plans 2008 Listing
4. MVP Health Care and IncentOne Partner to Provide Member Incentives for MVP and Preferred Care WellStyle Extras Program
5. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares
6. Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox
7. Mylan Declares Quarterly Preferred Stock Dividend
8. NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
9. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
10. Part D Advisors, Inc. Signs On as a TPAA Preferred Partner
11. PD-Rx Completes Call for Preferred A Stock

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...y (EAU) and Europa Uomo, the European,advocacy mo... entered into an,affiliated partnership as part o...ve,patient awareness in Europe with regards to ur...sson, Secretary-General of the EAU: "Thanks to thi...will gain access to the latest information on,opt...
(Date:11/30/2009)...knows the enormous joy and comfort that an animal ...ts are considered important members of the family ...search now documents the value of the human-animal...llness, physical impairment, dementia, abuse and t...ated youth and adults. , In two articles in a re...
(Date:11/30/2009)...as launched a series of clinical trials in order t...t. This approach involves the application of perso...cells from the patient him or herself and designed...ve and frequent malignant tumours. The new therapy...d with the standard, first-line treatment involvin...
(Date:11/30/2009)...uot;My Two-Year Old Eats Octopus," gives meal...rything. , (PRWEB) Novemb...ouse? Do you find yourself acting as a short-orde... – one focusing on packing lunches, a second...l-life parents’ questions – introduce ...
(Date:11/30/2009)... so do knees, internal injuries, study finds, , ...you,re a middle-age weekend warrior who likes to h... A new study suggests that high levels of physical...hat could lead to osteoarthritis. , The study f...le who showed no symptoms and had a healthy weight...
Breaking Medicine News(10 mins):Health News:The therapeutic benefits of the human-animal bond 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:New Videos Help Parents of Picky Eaters 2Health News:New Videos Help Parents of Picky Eaters 3Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3
...n,s reports of persistent, recent-onset symptoms l... difficulty eating or feeling full quickly and abd...d test may improve the early detection of ovarian ...h has found that when used alone, a simple four-qu...
... Garbose Family Special Delivery Unit at The Child...ind service for mothers,carrying fetuses with pren...e 22 Hundreds of families,gathered today to celeb...followed by the Center for Fetal Diagnosis and,Tre...
...truggling with the health fallout caused by a lack...y News) -- Most women don,t need a survey to tell ...eep-deprived and feel too sluggish to make it thro... women acknowledge that they just don,t get enough...
...n those under 80, could ease expected worldwide sh...ealthDay News) -- A blood substitute product calle... Phase III multi-center clinical trial, a new stud...) or an equivalent one unit (65 grams) of HBOC-201...
..., June 20 The United States,has provided $50,000 ...,organization Save the Children to assist people a...istrict of India., Shortages have emerged in rece...he United States, Save the,Children will assist po...
... June 20 The Department of,Agriculture is recomme...rom,Stump Acres Dairy farm in New Salem, York Coun...eria Monocytogenes contamination, Agriculture,Secr...quires they obtain,permits and be inspected to red...
Other Medicine News:Health News:Symptom screening plus a simple blood test improves early detection of ovarian cancer 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 3Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:PA Agriculture Department Warns Consumers About Raw Milk Sold by York County Dairy 2
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
VascoScrew E 8/60 M
VascoScrew P 6/60 M
VascoScrew E 6/60 S
VascoScrew E 5/60 PU M
Medicine Products: